Choose your location
New Zealand
English
Austria
Belgium
Denmark
Estonia
Finland
France
Iceland
Ireland
Italy
Latvia
Lithuania
Luxembourg
Netherlands
Norway
Portugal
Spain
Sweden
Switzerland
United Kingdom
Golden era in health care
As health care industry is undergoing a profound transformation, what separates speculative science from drugs with true clinical and commercial potential in an era of innovation and evolving patient needs?
The game-changing potential of GLP-1 drugs
The introduction of GLP-1s could revolutionise health care. These drugs are not only effective in treating obesity but also have the potential to combat over 200 related diseases, promising significant long-term health savings and improved patient outcomes.
Beyond diabetes and obesity
While GLP-1 receptors are concentrated in the pancreas, evidence is growing that GLP-1 drugs can interact directly with GLP-1 receptors found in other organs.
Brain
May reduce alcohol cravings, and early evidence suggests a possible role in avoiding neurodegenerative diseases such as Alzheimer's and Parkinson's.
Liver
May reduce fat buildup in those with fatty liver disease.
Lungs
May reduce inflammation in the lungs and other organs, although it's unclear how much of this is due to weight loss.
Kidneys
May preserve kidney function in those with chronic kidney disease.
Heart
May reduce inflammation in the heart and circulatory system.
Intestines
May speed the breakdown of fat cells to produce energy.
The ripple effects of GLP-1s
We believe we were early in understanding the promise of GLP-1s, below are just some of the ways GLP-1s have the potential to impact various sectors beyond healthcare.
Food and beverage
GLP-1s could shift consumer preferences towards healthier choices, impacting fast food and snack industries. Alcohol consumption may also decline as these drugs help combat addictive behaviours.
Insurance
Improved health outcomes could lower healthcare costs and claims, influencing health insurance premiums and policies.
Surgery
The demand for bariatric surgery may decrease, while eligibility for knee and hip surgeries could increase as patients achieve healthier weight.
Productivity and workforce
Healthier populations could lead to enhanced productivity, reduced absenteeism, and lower healthcare costs for employers, benefiting the overall economy.
Environment
Reduced food consumption and waste could positively impact sustainability goals and reduce the carbon footprint of food production and distribution.
Podcasts: The Impact of Future Health Care Innovations
items
The Long View: Interview with Dave Ricks, Chair and CEO, Eli Lilly
In this episode, Dave Ricks, Chair and CEO of Eli Lilly, shares his insights on the company’s major advancements in diabetes, obesity, and Alzheimer’s treatments, global drug access, manufacturing scale, and the role of innovation and AI in health care.
Biotech Frontiers: The Next Wave of Innovation
In this episode of “The Angle,” Jennifer Martin is joined by health care portfolio manager Sal Rais to explore how new ways of treating disease are improving human health, and how breakthrough drugs can potentially create value for biotech innovators.
The GLP-1 Revolution: Transforming Health Outcomes
Jeff Holford, health care analyst, joins host Jennifer Martin to discuss why new GLP-1 drugs signifies a potential seismic shift in how we manage obesity and related health conditions.
Beyond the Lab: Innovations in Life Sciences
In this episode, we zero in on the game-changing innovations that are taking place within life sciences, and discuss advancements that are fundamentally changing how we approach patient care, and the treatment of injury and disease.
How to get exposure to health care
Our approach to investing is truly global. With one of the most extensive and experienced buy-side global research engines in the industry, our investment teams discover investment opportunities you can be confident in.
T. Rowe Price Global Focused Growth Equity
T. Rowe Price Global Growth Equity
T. Rowe Price Global Impact Equity
T. Rowe Price Global High Income Bond
All information is as at 31 March 2024, unless specified.
Important Information
Available in New Zealand for Wholesale Investors only. Not for further distribution.
Equity Trustees Limited (“Equity Trustees”) (ABN: 46 004 031 298, AFSL: 240975), is the Responsible Entity for the T. Rowe Price Australian Unit Trusts ("the Fund"). Equity Trustees is a subsidiary of EQT Holdings Limited (ABN: 22 607 797 615), a publicly listed company on the Australian Securities Exchange (ASX: EQT).
This material has been prepared by T. Rowe Price Australia Limited ("TRPAU") (ABN: 13 620 668 895, AFSL: 503741) to provide you with general information only. In preparing this information, we did not take into account the investment objectives, financial situation or particular needs of any particular person. It is not intended to take the place of professional advice and you should not take action on specific issues in reliance on this information. Neither TRPAU, Equity Trustees nor any of its related parties, their employees or directors, provide and warranty of accuracy or reliability in relation to such information or accepts any liability to any person who relies on it.
Past performance is not a guarantee or a reliable indicator of future results. You should obtain a copy of the Product Disclosure Statement, which is available from Equity Trustees (Institutional Funds) or TRPAU (Institutional Investing New Zealand), before making a decision about whether to invest in the Fund named in this material.
The Fund’s Target Market Determination is available here (Fund Manager Details ). It describes who this financial product is likely to be appropriate for (i.e. the target market), and any conditions around how the product can be distributed to investors. It also describes the events or circumstances where the Target Market Determination for this financial product may need to be reviewed.
4792168